STORM Therapeutics wins Life Science Innovation Award
27 March 2018, Cambridge, UK: STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, today announced that it has won the Life Science Innovation Award at the Business Weekly Awards ceremony. Held at Queen’s College, Cambridge, the Awards Dinner attracts entries from across the East of England and is the longest-running B2B competition in the UK. The Awards pride themselves on early identification of world-leading businesses.
STORM Therapeutics was recognised by the judges for leading the field in a highly innovative area of drug discovery which has the potential to target novel disease mechanisms through the inhibition of RNA modifying enzymes.
Commenting on the award, Keith Blundy, CEO of STORM Therapeutics said: “We are very pleased to have been recognized for the Life Science Award, voted for by our peers in Cambridge. It is a credit to the team and our Investors, and a strong endorsement of STORM’s pioneering drug discovery programmes. As the first company tackling disease through harnessing the power of RNA epigenetics, we believe we are well positioned to build a world leading company.”
For further information:
STORM Therapeutics Ltd
T: +44 (0)1223 804174
Optimum Strategic Communications
Mary Clark, Hollie Vile
Tel: +44 203 714 1787
NOTES TO EDITORS
STORM Therapeutics, founded in 2015, is a University of Cambridge spin-out translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. It is the leading company currently tackling disease through modulating RNA modifying enzymes and is developing a unique platform to address these enzyme classes, including RNA methyltransferases.
STORM is backed by blue chip investors Cambridge Innovation Capital, M Ventures, Pfizer Ventures, IP Group and Taiho Ventures LLC, who share the founders’ ambitions to build a world-leading company in the field. To date, STORM Therapeutics has raised £16million of funding.